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Inhibition of multiplication of pneumonia virus of mice (PVM) and mumps 
virus by the  type specific  capsular polysaccharides of Friedliinder bacilli has 
been reported in previous papers  (1, 2). Not only does the polysaccharide in- 
hibit viral multiplication when  given as  long as 4  days  after inoculation of 
either virus, but also significant inhibition is obtained with only a few micro- 
grams of the purified material (1, 2). The available evidence indicates that the 
polysaccharide does not act directly upon either virus to cause inactivation nor 
does  the  substance  combine  with  either  agent  (1-3).  Also,  it  appears  that 
release of PVM or mumps virus from infected host ceils is not prevented by 
the complex carbohydrate (4).  These findings have led to the hypothesis that 
the polysaccharide acts upon the susceptible host cell to combine with, or com- 
pete  for,  some cell constituent which is present  in limited quantity, not re- 
quired to maintain life of the cell, but necessary for viral multiplication. 
If this postulate were valid, it would be anticipated that two verifiable pre- 
dictions should follow: (1)  Inasmuch as both PVM and mumps virus appear 
to  multiply in  discrete  cycles  (4,  5),  the  polysaccharide should  inhibit  the 
incremental increase in viral concentration when given during the latent period 
of the  cycle;  (2)  The  polysaccharide should limit  viral  multiplication after 
infection is well established but submaximal, and as a result (6) inhibit progress 
of  the pathological  lesion  (7).  In  order to  test  these predictions,  PVM  was 
selected as the agent of choice because: (1)  it produces fatal viral pneumonia 
in its natural host; (2) the qualitative and quantitative aspects of infection with 
the agent have been studied extensively (6,  8,  9);  (3)  the temporal limits of 
the latent period of a  single cycle of multiplication with the virus have been 
determined  (5). 
It is the purpose of this paper to show that the capsular polysaccharide of 
FriedlAnder bacillus, type B, not only inhibits the multiplication of PVM when 
given as long as 10 hours after a large inoculum of virus, but also modifies the 
course of the severe viral pneumonia induced in mice so that the majority of 
treated animals recover completely. 
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Materials and Methods 
Virus.--The strains of PVM  employed, the  method  of passage, and  means  of storage 
were identical with those described in the preceding papers (5, 6). 
Mice.--Albino Swiss mice  of the  Rockefeller Institute strain as well as similar strains 
from commercial breeders were employed. As a routine, each experimental group contained 
6 mice, 3 to 4 weeks of age. 
Hemagglu~ina~ion Titra~ions.--Suspensions  of infected  mouse lungs were prepared  either 
in 0.85 per cent NaCI buffered at pH 7.2 with 0.01 M phosphate buffer or in distilled water. 
The titrafions were performed in a manner identical with those previously described  (5, 8). 
Infec~idty Titrati.ons.--These  were carried out as in previous studies (10). 
Polysaccharide Preparati~ns.--The capsular polysaccharide of Friedl~nder bacillus,  type 
B  (Fr.B) was obtained from Dr. Walther F. Goebel, the Rockefeller Institute, New  York. 
Solutions of polysaccharide were prepared as previously described (2) and sterilized by heat- 
ing at either 70°C. for 30 minutes or 100°C. for 2 minutes. 
Immune Mouse Serum.--Mice were inoculated intranasally with a sublethal dose of PVM, 
less than 1.0 M.S.50, and in 2 weeks were injected intraperitoneally  with 0.5 cc. of a I0 per 
cent infected lung suspension containing about 104 M.S.50 doses. The animals were bled from 
the heart 2 weeks later. Serum was stored without preservative at 4°C. 
E~EI~I~gRNTAL 
Effect  of Capsular Polysaccharide of Friedlander  Bacillus,  Type B,  on First 
Cycle of Multiplication of PVM.--If the multiplication of PVM is inhibited by 
Fr.B. as a  result  of some effect within the  host  cell as  has been  postulated 
(1),  the polysaccharide should be active during the latent period of a  single 
cycle of multiplication of the virus. As shown in the preceding paper (5), the 
latent  period with  PVM  is  of  about  15  hours'  duration.  Experiments  were 
carried out to determine if viral multiplication could be inhibited by injection 
of Fr.B  at various times during  the latent period, and  whether  there  was  a 
critical time after which the substance would have no significant effect upon 
the formation of new viral particles during a  single multiplication cycle. 
Mice were inoculated intranasally with 10  s.5 M.S.50 doses of PVM, and various groups 
were each given a single intranasal injection of Fr.B, 0.1 mg. per mouse, at 2, 4, 8,  10, or 
12 hours afterwards. For controls, other infected mice were given saline, 0.05 co. intranasally, 
at corresponding periods. Groups of mice from each series were killed at 4- to 8-hour intervals 
commencing 20 hours after inoculation of PVM. The lungs were stored at -28°C. until the 
completion of the experiment after which suspensions were made in distilled  water and hemag- 
glutination titrations carried out with 0.05 per cent mouse RBC as described previously (5). 
The mean results of three separate experiments are presented graphically in 
Fig. 1. Intranasal injection of Fr.B as long as 4 hours after initiation of infec- 
tion with a  large inoculum of PVM  completely inhibited viral multiplication 
as determined by the hemagglutination technique.  Even when polysaccharide 
was injected as late as  10 hours after viral inoculation, there was significant 
inhibition of multiplication. However,  when  the inoculation preceded the in- 
jection of Fr.B by 12 hours, there was no definite decrease in the quantity of H.  S.  GINSBERG  AND  F.  L.  HORSFALL,  JR..  163 
virus formed during a  single cycle of multiplication  although there was a  con- 
sistent  retardation  of  the  incremental  period.  That  there  was  a  progressive 
decrease in the inhibitory action of the polysaccharide from 4 to 12 hours during 
the latent period may be explained  on either of two bases:  (1)  that  the  time 
required  for Fr.B  to reach  all  infected  cells  and  to produce its  effect is pro- 
longed;  or  (2)  that  viral  particles  are  formed  at  slightly  different  rates  and 
therefore that  some particles reach  a  stage of development at which  Fr.B  is 
ineffective  before  other  particles. 
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FIa. 1. Inhibition  of multiplication  of PVM in the mouse lung during  the latent period 
of the first cycle of multiplication. A single injection of 0.1 mg. of Fr.B per mouse was given 
intranasally  at the indicated  time after inoculation of 10  s.s M.S.S0 doses of virus. 
Effect of Fr.B Injected at End of Latent Period.aThat  the polysaccharide did 
not markedly alter  the  first  cycle of multiplication  of PVM  when it  was in- 
jected  12 hours  after  a  large inoculum  was demonstrated  above  (cf.  Fig.  1). 
Inasmuch as earlier work (1) indicated that inhibition could be obtained late, 
i.e.,  4th  day,  in  the  infectious  process,  it  seemed  probable  that  when  poly- 
saccharide  was given late  enough in  the first  cycle to be ineffective it would 
cause inhibition  of the next  cycle of multiplication. 
Fr.B,  0.1 mg. per mouse, was injected intranasally  18 hours after inoculation with 10  a.s 
M.S.50 doses of PVM, and the viral concentration  in the mouse lungs was then determined 
at frequent intervals.  Except for the time of polysaccharide injection, and differences in the 
periods at which groups of mice were killed, these experiments were carried out in a manner 
similar to those described in the preceding section. 
The results  of these  experiments  are presented  in Fig.  2. As was to be ex- 
pected,  Fr.B  injected  18  hours  after  PVM  did  not  demonstrably  alter  the 
first cycle of viral multiplication, but its effect on the ensuing cycle was marked. 
It should be emphasized that the latent period with  this virus is of the order 164  THERAPY  OF  INFECTION  WITH  PVM 
of 15 hours (5) and in terms of the hypothesis under consideration it was not 
to be anticipated that the polysaccharide would inhibit multiplication during 
a  single cycle when given after completion of the latent period. Not only was 
multiplication during  the subsequent cycle inhibited, but also  a  definite de- 
crease in viral concentration occurred during this time period. As was demon- 
strated in the preceding paper (5), when PVM is prevented from multiplying, 
the concentration of the agent progressively decreases in the mouse lung. 
The evidence presented in Figs. 1 and 2 indicates that during the first two- 
thirds  of the  latent  period,  multiplication  of PVM  is  inhibited  by a  single 
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Fz¢. 2. Inhibition of multiplication of PVM in the mouse lung during the second cycle  of 
multiplication. A single injection of 0.1 rag. of Fr.B per mouse was given intranasally 18 
hours after inoculation of 10  s.s M.S.50 doses of virus. 
injection of 0.1  mg. of Fr.B. Thereafter, no significant inhibition is obtained 
during the initial cycle. Giving the polysaccharide after the completion of the 
latent period of the  first cycle of multiplication results  in  its being present 
before ~he next cycle commences. As a consequence, multiplication of the virus 
during the second cycle is inhibited. 
Effect  of Fr.B  on the Mouse Lung.--While  carrying out the experiments de- 
scribed in this report, it was  found that  the intranasal  injection of Fr.B  in 
amounts of 0.1  rag. or more per mouse often resulted in the development of 
some pulmonary lesions demonstrable  1 to 2 days later. The lesions were ir- 
regular in distribution and size,  seldom involved more than 30 per cent of the 
lung,  and reached maximal size 4  days after the injection. Disappearance of 
the lesions occurred rapidly and by the 6th day almost all had resolved com- 
pletely. Microscopic examination showed the lesions to consist mainly of areas 
of atelectasis although in the gross they were indistinguishable from areas of H. S. GINSBERG AND F. L. HORSI~ALL,  JR.  165 
pneumonic  consolidation.  It  seemed  of  some  importance  to  determine  the 
relationship of  such  lesions  to  the capacity of the polysaccharide to inhibit 
multiplication of PVM  in the mouse lung. 
It was found that  the capacity to produce pulmonary lesions was directly 
related to the viscosity of the polysaccharide solutions. As is shown in Fig. 3 
when 0.02 rag. of Fr.B was injected intranasally, no lesions were produced in 
any animal, and yet this small quantity of polysaccharide inhibited multipli- 
cation of PVM markedly. The same preparation of Fr.B  was  oxidized with 
0.03 ~  periodic acid at pH 5.0 for 160 minutes and 24 hours, respectively, as 
previously described (2).  1 As is demonstrated in Fig. 3, 0.1 mg. of Fr.B which 
had been oxidized for 160 minutes produced definite lesions in the lung, whereas 
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FIG. 3.  Extent and duration of lesions caused in the mouse lung by intranasal injection 
of different quantities of Fr.B before and after treatment with 0.03 x¢ HIO~ at pH 5.0. 
a  similar  quantity oxidized for 24  hours produced ordy equivocal lesions in 
50  per  cent  of  the  injected  mice.  Despite  the  fact  that  Fr.B  treated  with 
periodate caused only minimal lesions, it retained in undiminished degree its 
ability to inhibit multiplication of PVM.  Similar results were obtained pre- 
viously (1). These findings indicate that the production of transient pulmonary 
lesions by certain preparations of Fr.B is not directly related to inhibition of 
viral multiplication.  In  this connection it has  been demonstrated previously 
(2)  that large quantities of Fr.B produce no demonstrable tesions in the chick 
embryo or its chorioallantoic membrane and yet the multiplication of mumps 
virus is inhibited in this host species by the polysaccharide. 
Modification of the Course of PVM Pneumonia by Fr.B.--The evidence pre- 
sented in a  preceding paper  (6)  indicates that  the extent of the pathological 
1  The oxidation procedures  were kindly carried out by Dr. Walther F. Goebel, the Rocke- 
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lesion produced in the mouse lung is directly related  to the concentration of 
PVM present  at  a  given time.  It appears,  from the  data  given above,  that 
multiplication of the virus can be interrupted by Fr.B in the first cycle if the 
polysaccharide is  injected during the first two-thirds of the latent period.  In 
addition, subsequent cycles of multiplication of the agent are inhibited by the 
substance  (1).  These  findings  made  it  seem  probable  that  reduction  in  the 
quantity of PVM  formed as a  result  of inhibition  of multiplication by Fr.B 
would also reduce the extent of the pneumonia which developed. It was thought 
that  if the  development of the pathological lesion were  sufficiently impeded 
the animals would recover from the infection. In order to test this possibility, 
the  following experiments were  carried out:- 
Numerous mice were inoculated intranasally with 102 M.S.50 doses of PVM.  One large 
group of inoculated mice was given Fr.B, 0.02 mg. per mouse, intranasaUy 2 days after PVM 
inoculation and another group was treated similarly 3 days following the virus. Other groups 
of inoculated animals were injected with saline intranasally 2 and 3 days, respectively, fol- 
lowing the virus. Groups of 6 mice in each series were killed at 2-day intervals beginning 
4 days after infection. The lung lesions were scored as described previously (10), and the 
lungs were removed and stored at -28°C. until the completion of the experimental period. 
Hemagglutination titrations and, in  certain instances, infectivity titrations  were carried 
out on 10 per cent lung suspensions prepared in saline. Hemagglutination titers were deter- 
mined with a final concentration of 0.4 per cent mouse RBC; because of this and the fact 
that the suspensions were prepared in saline, the titers are 16-fold  lower than those for equiv- 
alent viral concentration determined by the modified procedure described in the preceding 
paper (5). The experimental period for each group was determined from the mean survival 
time. 
The results of a typical experiment are shown in Fig. 4. The results obtained 
in the two control series, those given saline 2 and 3 days, respectively, following 
PVM,  were  almost  identical  and  are  presented  together  as  mean  values  in 
both  the  upper  and lower portions of the  graph.  The disease  was uniformly 
fatal in the two control series;  all mice had died by the 7th day at which time 
complete consolidation of the pulmonary tissue, i.e.,  100 per cent, had occurred. 
Mice which received a  single  intranasal  injection of 0.02  mg. of Fr.B  2 days 
after inoculation with PVM showed a much less extensive disease.  At the time 
of  greatest  pulmonary  involvement,  i.e.,  6  days,  only  43  per  cent,  on  the 
average,  of the lung was consolidated as a  result  of the viral infection. Evi- 
dence of resolution was apparent  at  10 days, at  16 days only small areas  of 
gray consolidation remained, and all animals survived the experimental period. 
When 0.02 mg. of Fr.B was given as long as 3 days after inoculation, the course 
of the pneumonic process also was modified markedly. The pulmonary lesions 
were somewhat more extensive than in mice treated earlier in the disease,  but on 
the average the largest amount of lung tissue which showed consolidation was 
only 57 per  cent,  and  66 per  cent of the  animals  survived the  experimental 
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In  the lower portion of Fig.  4  is shown  the  concentration of virus in  the 
same lungs as measured by hemagglutination titration. The curve of increase 
in the quantity of PVM in the lungs of control mice closely approximated that 
observed in earlier studies  (6,  8); maximal concentration was reached 6 days 
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FIG. 4.  Relation between the degree of inhibition of multiplication of PVM in the mouse 
lung and the extent of restriction in the amount of pneumonia. A single injection of 0.02 rag. 
of Fr.B per mouse was given intranasally either 2 or 3 days after inoculation with 102 M.S.50 
doses of virus. Lung lesions and viral concentration were determined, in  each instance in 
the same animals. All control mice died by the 7th day. 
after inoculation of the virus. The increase in viral concentration in the lungs 
of mice that had received Fr.B either 2  or 3  days following inoculation was 
markedly restricted and it appears that not more than one cycle of multipli- 
cation was  completed after the polysaccharide was  given. After the 6th day 
the concentration of PVM in the lungs began to decrease and after 10 days 
no virus was demonstrable. Infectivity titrations with lung suspensions from 168  THERAPY  OF II~ECTIOI~  WITH  PVM 
selected groups of mice in this experiment confirmed the results obtained with 
the hemagglutination technique and showed that there was a  quantitatively 
similar difference in the amount of infective virus in the lungs of Fr.B treated 
animals as compared to those of controls. 
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FIo.  5.  Lack of effect of PVM immune mouse serum on the multiplication of PVM in 
the mouse lung and on the development of pneumonia when serum was given intmnasally 2 
days after 10  ~ M.S.50 doses of virus. The serum had a  hemagglutination-inhibil;ion titer of 
1:1024 against 8 units of PVM and completely prevented infection when given with or before 
the virus. 
Effect of Immune Serum on the Course of PVM Pneumonia.--The capacity of 
Fr.B to inhibit multiplication of PVM and to modify the course of pneumonia 
induced with the agent has been postulated  (2, 4)  to  be due to an effect of 
the polysaccharide upon the susceptible host cell. The polysaccharide, unlike 
specific antibody against the virus, does not combine with the agent and also 
does not prevent adsorption to susceptible cells  (1,  2).  If the mechanism of H.  S.  GINSBERG  AND  1  ¢.  L.  HORSFALL~ JR.  169 
action of Fr.B is as different from that of neutralizing antibody as has been 
thought, the injection of potent immune serum well after initiation of infection 
should  not  be  followed by results  similar  to  those obtained with  the  poly- 
saccharide. 
Experiments were carried out in a manner identical with that described in the preceding 
section. 0.05  cc. of PVM immune mouse serum, diluted 1:2 with saline and inactivated at 
56°C.  for 30 minutes, was injected intranasaUy in mice 2 days after the inoculation of 10  ~ 
M.S.50 doses of PVM. 
The results of a typical experiment are presented in Fig. 5. It is evident that 
there was no significant difference in either the concentration of PVM in the 
lungs of mice or the lesions induced by the virus whether immune serum was 
given at 2 days or was not given. The immune serum employed had a titer of 
hemagglutination-inhibiting antibodies of 1:1024 which correlates closely with 
the titer of neutralizing antibodies (8),  and when injected a  few hours before 
inoculation of the virus completely prevented infection of  the mouse lung. It 
appears clear that, when given 2 days after inoculation of PVM, potent  and 
specific immune serum had no demonstrable effect upon multiplication of the 
virus or upon the course of the pneumonic process and failed to reproduce the 
effects caused by Fr.B under identical conditions. 
DISCUSSION 
The evidence obtained in this study indicates that inhibition of the multi- 
plication of PVM  by the  capsular polysaccharide of Friedl/inder bacillus  is 
associated  with  a  reduction  in  the  extent  of pneumonia  induced  with  the 
virus.  If viral  multiplication is  restricted  by treatment at  3  days with  the 
polysaccharide so  that  the  concentration of the  agent in  the  lung does  not 
exceed  about  10  per  cent  of the  maximal value,  the  amount of pneumonia 
which develops does not go much beyond 55 per cent of the maximal value 
and most mice recover. If viral concentration is held, by similar treatment at 
2 days, to about 3 per cent of the limiting value, then the extent of the lung 
lesion does not exceed 40 per cent of the limiting value and all mice recover. 
The data suggest that the extent of the pneumonic process is approximately 
what would be predicted (6) from the viral concentration attained and provide 
support for the hypothesis that active multiplication of PVM leads to abnor- 
malities in  the host cells  which, in turn,  result in the  development of gross 
lesions. If the amount of pneumonia is a function of the degree of viral multi- 
plication,  a  concept developed  in  the  accompanying paper  (6),  it  would be 
expected  that  a  substance  capable  of  inhibiting multiplication  should  also 
restrict the pneumonic process.  It appears that this is the case. 
It is noteworthy that  specific  neutralizing antibody injected 2  days after 
inoculation with the  virus  appears  to have no effect upon  multiplication or 170  THERAPY  OF  INFECTION  WITH  PVM 
upon the course of pneumonia induced with PVM. This finding lends further 
credence  to  the  hypothesis that  the polysaccharide  does  not act  upon  the 
viral particle, as does antibody, but instead exerts its effect by preventing the 
formation of new viral particles by the susceptible host cell. 
That the polysaccharide inhibits some relatively late step in the formation 
of PVM is suggested by the finding that Fr.B inhibits multiplication of virus 
when injected as late as 10 hours after the beginning of the latent period of 
the multiplication cycle. It appears that the substance is effective when given 
at any time during the first two-thirds of the latent period but is ineffective 
after four-fifths of the  period  has  been  completed.  The  essential  step,  pre- 
sumably blocked by the polysaccharide, is passed  through by the multiplying 
virus before the 12th hour of the latent period but not before the 10th hour. 
Inhibition caused by the substance in the second or in subsequent cycles of 
multiplication would then be explained on a similar basis. 
In  studies on  the  effect of  proflavine on  the  multiplication of  bacterial 
viruses, T~ and T~, Foster (11) showed that inhibition was obtained when the 
substance was added during the first half of the latent period but not later in 
the  cycle. Moreover,  Cohen and Anderson  (12)  found that 5-methyltrypto- 
phane inhibited multiplication of T~ virus only if the substance was introduced 
within 12  to  14 minutes after infection, which amounts to about half of the 
latent period. Studies now in progress in this laboratory indicate that a similar 
time relationship holds with mumps virus in the chick embryo; multiplication 
appears to be inhibitable by Friedl~nder'polysaccharide during the first half 
of the latent period but not later in the cycle. 
SUMMARY 
Inhibition of the multiplication of PVM by the capsular polysaccharide of 
Friedl~tnder bacillus, type B, is associated with restriction in the development of 
pneumonia induced with the virus in the mouse lung. The extent of the pneu- 
monic process appears to be a  function of the degree of viral multiplication; 
the greater the inhibition of multiplication, the less extensive is the pneumonia 
and the more probable  is the recovery of animals treated with the polysac- 
charide. Effective therapy of pneumonia induced in mice with PVM is obtained 
with a  single injection of 0.02  rag. of the substance given intranasally either 
2 or 3 days after inoculation. Under appropriate conditions, treated animals 
recover completely from a  viral  infection which is,  in control animals,  uni- 
formly fatal. 
The polysaccharide produces inhibition if given in the first two-thirds of the 
latent period of the multiplication cycle, i.e.,  within 10 hours, but is ineffective 
when given at  12 hours or later. However, the second cycle and subsequent 
cycles are inhibited irrespective of the time the substance is injected during the H.  S.  GINSBERG  AND  F.  L.  HORSFALL~  JR.  171 
first cycle of multiplication. The findings are discussed in relation to a  theory 
regarding the mechanism of action of the polysaccharide. 
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